Testing LY4405094 in healthy people and people with Alzheimer’s disease

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This is a Phase 1 interventional study evaluating LY4405094 in both healthy volunteers and individuals with Alzheimer's disease. It aims to characterize safety, absorption, distribution, and pharmacokinetics, including brain fluid exposure in healthy participants and biomarker brain protein levels in Alzheimer’s patients. The study involves a short CRU stay for healthy participants and a longer stay for those with Alzheimer's disease, with placebo-controlled elements and an amyloid imaging agent used as part of the protocol. Duration ranges up to 25 weeks depending on cohort, with multiple study arms including LY4405094 and placebo. Lead sponsor is Eli Lilly and Company, with study sites in California.

Why it matters

Who can join: the full rules

Inclusion Criteria:

* Participants must meet eligibility criteria in the ATMP screening protocol before entry into the treatment study.

Exclusion Criteria:

* Have known allergies to LY4405094, related compounds (including remternetug), or any components of the formulation, including LY4405094.
* Have known allergic reactions to adhesive or hydrogels or a family history of adhesive skin allergies.

Where it's running

• Fortrea Clinical Research Unit
  Daytona Beach, Florida, United States Recruiting
• CenExel ACT
  Anaheim, California, United States Not yet recruiting
• Irvine Clinical Research
  Irvine, California, United States Not yet recruiting
• Collaborative Neuroscience Network - CNS
  Los Alamitos, California, United States Not yet recruiting
• K2 Medical Research - The Villages
  Lady Lake, Florida, United States Not yet recruiting
• K2 Medical Research
  Maitland, Florida, United States Not yet recruiting

Study contacts

• Study coordinator: Trial questions or participation questions: 1-877-CTLILLY (1-877-285-4559) or
• Email: LillyTrials@Lilly.com
• Phone: 1-317-615-4559

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Test of amyloid-targeting medicines in healthy people and adults with Alzheimer’s

  This trial tests the safety and tolerability of amyloid-targeting drugs, plus a placebo, in healthy adults and in people with Alzheimer’s disease to see if the drugs can reduce brain amyloid plaques.

  Recruiting at 3 sites Phase 1 Eli Lilly and Company · Anaheim, California and 18 other locations · NCT07787169

• Donanemab follow-up dosing in participants who previously completed TRAILBLAZER-ALZ 3-EXT

  This study tests whether giving annual donanemab doses benefits people with Alzheimer's disease who finished the prior trial.

  Recruiting at 60 sites Phase 3 Eli Lilly and Company · Phoenix, Arizona and 61 other locations · NCT07602582

• Blood biomarker cohort for memory disorders in older adults

  This observational cohort will collect blood samples and brain imaging data from adults 50+ with memory disorders and a small group of healthy young adults to help find biomarkers.

  Recruiting Yonsei University · Seoul, Seodamun-gu · NCT07880275

• Tau changes after hip or knee replacement surgery

  Researchers will see if brain tau changes after hip or knee surgery and whether these changes relate to inflammation and thinking abilities.

  Recruiting Uppsala University Hospital · Uppsala · NCT07871487

• Low-Dose Whole-Brain Radiation Therapy With HeLaXON 1X in Mild Alzheimer's Dementia

  This study will test whether a low-dose brain radiation treatment using HeLaXON helps people with mild Alzheimer's dementia improve or stabilize thinking and daily function.

  Recruiting ReadyCure Inc. · Cheonan, Chungcheongnam-do · NCT07863011

• Cervical lymphatic surgery to see if it helps people with mild Alzheimer’s

  We’re testing a surgical approach in people with mild Alzheimer’s to see if creating alternative neck lymph drainage routes can affect brain biomarkers and daily function.

  Recruiting at 2 sites Maliszewski Daniel · Gdansk and 1 other locations · NCT07857759

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.